Paul Smith, the new CEO, will help in the expansion of BioAscent’s discovery services offering
BioAscent Discovery has appointed Paul Smith as CEO, in preparation for the expansion of BioAscent’s discovery services offering. BioAscent will be developing a range of complementary discovery services.
Smith, an experienced senior management and BD executive in the pharmaceutical/CRO arena, brings comprehensive knowledge of the drug development process, from discovery to clinical research, gained over three decades in the industry. Prior to joining BioAscent, he was CEO of CXR Biosciences, a Dundee-based ADME-Tox CRO which he successfully re-engineered from a loss-making business into a focussed preclinical CRO with sector-beating profitability, and subsequently sold to Concept Lifesciences.
Smith said, “Our new house facility already offers unparalleled infrastructure for managing solid and liquid compounds and I’m really looking forward to work with the great team here at BioAscent to build a more complete range of discovery services. Our aim is to be the outsourced discovery partner of choice.”